Poxel announces positive pharmacokinetic (pk) / pharmacodynamic (pd) study results for pxl770, a direct ampk activator for the treatment of nash

Poxel sa (euronext: poxel - fr0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, in
MDGL Ratings Summary
MDGL Quant Ranking